drugset / Trial / NCT01913028
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects
RandomizedParallel-groupSingle-blindBasic science
Summary
The purpose of this study is to assess safety, tolerability, pharmacokinetics and immunogenicity of MEDI9929 following administration of single ascending doses in healthy male Japanese subjects.
Timeline
- Start
- 2013-08
- Primary completion
- 2014-01
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tezepelumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.